Lawrence Otto Klein is COO at CRISPR Therapeutics AG (CRSP). They have made 8 open-market trades across 2 companies since 2019, most recently 2026-10-01.
CIK 0001762583
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases since 2020, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ORKA | 923,128 | $66.5M |
| CRSP | 26,909 | $1.3M |
| DYN | 10,725 | $153K |
| JSPR | 24,500 | $12K |
| Total | $67.9M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ORKA | SELL · 10b5-1 | 2026-10-01 | 2026-10-02 | $83.62 | $2.1M | -9.8% | — | — |
| ORKA | SELL | 2026-09-15 | 2026-09-15 | $95.71 | $235K | -9.1% | -20.5% | — |
| ORKA | SELL · 10b5-1 | 2026-09-01 | 2026-09-01 | $91.83 | $6.9M | +1.8% | -11.6% | — |
| ORKA | SELL | 2026-06-15 | 2026-06-15 | $69.69 | $120K | +32.0% | +26.3% | +39.8% |
| ORKA | SELL | 2026-03-16 | 2026-03-17 | $41.30 | $71K | +7.8% | +62.5% | +67.1% |
| CRSP | SELL | 2021-03-23 | 2021-03-25 | $128.12 | $24.1M | +3.7% | +18.7% | +14.3% |
| CRSP | SELL | 2021-01-15 | 2021-01-20 | $215.32 | $9.0M | -14.5% | -23.2% | -37.2% |
| CRSP | SELL | 2020-06-24 | 2020-06-26 | $75.75 | $8.8M | +26.0% | +23.4% | +11.6% |
| CRSP | SELL | 2020-05-11 | 2020-05-13 | $60.39 | $3.0M | +17.2% | +5.9% | +58.1% |
| CRSP | SELL | 2019-07-10 | 2019-07-12 | $50.02 | $2.0M | +0.1% | -0.3% | -25.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.